Adaptimmune Therapeutics PLC closed an underwritten public offering of its American depositary shares for net proceeds of about $61.8 million.

The company sold 15,700,223 shares at $4.20 per share, including 1,400,223 shares sold to underwriters.

Adaptimmune plans to use the net proceeds to advance its pipeline of SPEAR T-cell candidates through clinical trials and for other general corporate purposes.

Citigroup, Cowen and Co. and Leerink Partners acted as joint book-running managers for the offering. Guggenheim Securities acted as lead manager.